ReviewACS omega2025
Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous leishmaniasis (CL) is a parasitic infection caused by Leishmania species, affecting millions worldwide. The current treatment options for CL have several limitations, including low efficacy, inability to reach the target site, potential toxicity, and longer treatment duration, leading to poor patient compliance. Therefore, there is an urgent need for alternative treatments, especially topical ones, that are more effective, safe, and patient-friendly. Although numerous reviews have described the advantages of a wide range of nanoparticles in the treatment of CL, this review narrows its focus to the utilization of novel lipid-based nanocarriers for the topical treatment of CL, offering an in-depth analysis of the topical potential and mechanism of skin permeation of these lipidic nanocarriers. Lipid-based nanostructures such as liposomes, solid lipid nanoparticles, and nanostructured lipid carriers have been extensively studied for CL treatment, either alone or in combination with other drugs or therapies. These carriers can improve the bioavailability, stability, and efficacy of the drug, target the infected site, and reduce adverse effects on healthy tissues. Moreover, these can be easily formulated into different dosage forms, such as creams, gels, or ointments, for convenient topical application. Despite the many benefits of lipid-based carriers, there are still some challenges that need to be addressed, such as optimizing the formulation parameters, ensuring the reproducibility and scalability of the process, and evaluating the long-term safety and efficacy in clinical trials. This study aims to provide a comprehensive overview of the current state-of-the-art lipid-based nanocarriers for topical treatment of CL, covering the recent advances, limitations, clinical evidence, and prospects of this promising approach. In addition, the skin and macrophage targeting potential of various lipid-based nanocarriers is also discussed, which is especially helpful in treating the lesions of CL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.